RESUMEN
PURPOSE: Comparison of the dissociation kinetics of rapid-acting insulins lispro, aspart, glulisine and human insulin under physiologically relevant conditions. METHODS: Dissociation kinetics after dilution were monitored directly in terms of the average molecular mass using combined static and dynamic light scattering. Changes in tertiary structure were detected by near-UV circular dichroism. RESULTS: Glulisine forms compact hexamers in formulation even in the absence of Zn2+. Upon severe dilution, these rapidly dissociate into monomers in less than 10 s. In contrast, in formulations of lispro and aspart, the presence of Zn2+ and phenolic compounds is essential for formation of compact R6 hexamers. These slowly dissociate in times ranging from seconds to one hour depending on the concentration of phenolic additives. The disadvantage of the long dissociation times of lispro and aspart can be diminished by a rapid depletion of the concentration of phenolic additives independent of the insulin dilution. This is especially important in conditions similar to those after subcutaneous injection, where only minor dilution of the insulins occurs. CONCLUSION: Knowledge of the diverging dissociation mechanisms of lispro and aspart compared to glulisine will be helpful for optimizing formulation conditions of rapid-acting insulins.
Asunto(s)
Hipoglucemiantes/química , Insulina Regular Humana/química , Humanos , Inyecciones Subcutáneas , Insulina/análogos & derivados , Insulina/química , Insulina Aspart/química , Insulina Lispro/química , Insulina de Acción Corta , Cinética , Peso Molecular , Fenoles/química , Agregado de Proteínas , Estabilidad Proteica , Relación Estructura-Actividad , Zinc/químicaRESUMEN
Scope of the study was (1) to develop a lean quantitative calibration for real-time near-infrared (NIR) blend monitoring, which meets the requirements in early development of pharmaceutical products and (2) to compare the prediction performance of this approach with the results obtained from stratified sampling using a sample thief in combination with off-line high pressure liquid chromatography (HPLC) and at-line near-infrared chemical imaging (NIRCI). Tablets were manufactured from powder blends and analyzed with NIRCI and HPLC to verify the real-time results. The model formulation contained 25% w/w naproxen as a cohesive active pharmaceutical ingredient (API), microcrystalline cellulose and croscarmellose sodium as cohesive excipients and free-flowing mannitol. Five in-line NIR calibration approaches, all using the spectra from the end of the blending process as reference for PLS modeling, were compared in terms of selectivity, precision, prediction accuracy and robustness. High selectivity could be achieved with a "reduced" approach i.e. API and time saving approach (35% reduction of API amount) based on six concentration levels of the API with three levels realized by three independent powder blends and the additional levels obtained by simply increasing the API concentration in these blends. Accuracy and robustness were further improved by combining this calibration set with a second independent data set comprising different excipient concentrations and reflecting different environmental conditions. The combined calibration model was used to monitor the blending process of independent batches. For this model formulation the target concentration of the API could be achieved within 3 min indicating a short blending time. The in-line NIR approach was verified by stratified sampling HPLC and NIRCI results. All three methods revealed comparable results regarding blend end point determination. Differences in both mean API concentration and RSD values could be attributed to differences in effective sample size and thief sampling errors. This conclusion was supported by HPLC and NIRCI analysis of tablets manufactured from powder blends after different blending times. In summary, the study clearly demonstrates the ability to develop efficient and robust quantitative calibrations for real-time NIR powder blend monitoring with a reduced set of powder blends while avoiding any bias caused by physical sampling.
Asunto(s)
Cromatografía Líquida de Alta Presión/métodos , Excipientes/química , Naproxeno/administración & dosificación , Espectroscopía Infrarroja Corta/métodos , Calibración , Carboximetilcelulosa de Sodio/química , Celulosa/química , Química Farmacéutica/métodos , Manitol/química , Modelos Teóricos , Naproxeno/química , Polvos , Reproducibilidad de los Resultados , Comprimidos , Tecnología Farmacéutica/métodos , Factores de TiempoRESUMEN
The selection of a suitable vehicle for preclinical compound profiling is a very important task during the early developmental phases to ensure the quality of candidates and the speed of compound progression. Apart from biopharmaceutical and pharmaceutical technical considerations, i.e. solubility/dissolution improvement or route of application, other aspects have to be taken into account, as well: (i) availability and quality of the compound, (ii) tolerability of the vehicle in the selected animal model, (iii) developmental possibilities, i.e. whether the formulation can be transformed into a clinical one. The approach described in this paper is based on results of team collaboration between functions involved in the conduct of animal experiments (Pharmacology, Pharmacokinetics, Toxicology, and Pharmaceutical Sciences). Very early in vivo studies should be performed with dissolved API as available information on solid-state characteristics is usually limited at this time. Later studies should be performed with developable formulations, taking into consideration pharmacological, toxicological, and pharmaceutical requirements. At this stage, delivery strategies (i.e. advanced formulations and/or alternative routes of administration) should be considered, as well. In addition, a minimum level analytical characterization of compounds and formulations used in animal studies is required to explain unexpected results.